Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03882580
Other study ID # CIC1421-19-05
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date March 1, 2019
Est. completion date March 1, 2025

Study information

Verified date April 2023
Source Groupe Hospitalier Pitie-Salpetriere
Contact Joe-Elie Salem, MD, PhD
Phone (0)1 42 17 85 33
Email joe-elie.salem@aphp.fr
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Several Drugs used in routine care in oncology induce rare but often severe or fatal cardiovascular or metabolic side effects. This study will investigate, evaluate, report and treat the cardiovascular side effects of anticancer drugs, through a specific cardiovascular routine checkup and follow-up taking place in several Cardio-oncology programs throughout France. The different including centers will be: Assistance Publique - Hôpitaux de Paris (APHP.6: Pitié-Salpétrière, Saint Antoine and Tenon's hospitals, Paris, France).


Description:

Several anticancer and supportive care drugs used in oncology have an impact on the cardiovascular and metabolic systems, leading to a wide range of cardiovascular and metabolic disorders and side effects. Those are poorly described, due to the evolution of the anticancer pharmacopeia, and recent recognition of these adverse events. This study will investigate the potential benefits of a specialized cardio-oncology check-up and follow-up in this context.


Recruitment information / eligibility

Status Recruiting
Enrollment 5000
Est. completion date March 1, 2025
Est. primary completion date March 1, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Suffering a cancer - Evaluated within a cardio-oncology program Exclusion Criteria: - None

Study Design


Intervention

Drug:
Anti-Cancer Agents
Drugs and treatments used in cancer inducing cardiovascular and metabolic side effects

Locations

Country Name City State
France AP-HP, Pitié-Salpêtrière Hospital, Department of Pharmacology, CIC-1421, Pharmacovigilance Unit, INSERM Paris
France AP-HP, Saint-Antoine Hospital, Department of cardiology Paris
France AP-HP, Tenon Hospital, Department of Cardiology Paris

Sponsors (1)

Lead Sponsor Collaborator
Groupe Hospitalier Pitie-Salpetriere

Country where clinical trial is conducted

France, 

References & Publications (1)

Salem JE, Allenbach Y, Vozy A, Brechot N, Johnson DB, Moslehi JJ, Kerneis M. Abatacept for Severe Immune Checkpoint Inhibitor-Associated Myocarditis. N Engl J Med. 2019 Jun 13;380(24):2377-2379. doi: 10.1056/NEJMc1901677. No abstract available. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Number of patients having a benefit after this specific cardio-oncology check up and follow up 5 years
Secondary Evaluating the overall survival of patients suffering from cardiovascular or metabolic side effect of oncology treatments 5 years
Secondary All relevants staisticals associations between adverse events and anticancer drugs 5 years
Secondary All relevant statistical associations between cardiovascular toxicities, and anticancer drugs 5 years
Secondary All relevants statistical associations between cardiovascular side effects induced by oncology treatments , and other potentials kind of side effects induced by oncology treatments 5 years
Secondary All relevant statistical associations between duration and type of treatement used to manage cardiovascular side effects induced by oncology treatments, and overall survival 5 years
Secondary All relevants statistical associations between differential features of subgroups of patients, and the occurence of cardiovascular side effects induced by oncology treatments 5 years
Secondary All relevant statistical associations between new therapies to treat or prevent the cardiovascular side effects induced by oncology treatments, and overall survival 5 years
Secondary All relevant statistical associations between the pre therapeutic cardiovascular checkup and follow up for patients with cancer or history of cancer, and the occurence of cardiovascular toxicities of oncology treatments. 5 years
Secondary All relevant statistical associations between metabolic toxicities, and anticancer drugs 5 years
Secondary All relevants statistical associations between metabolic side effects induced by oncology treatments , and other potentials kind of side effects induced by oncology treatments 5 years
Secondary All relevant statistical associations between duration and type of treatement used to manage metabolic side effects induced by oncology treatments, and overall survival 5 years
Secondary All relevants statistical associations between differential features of subgroups of patients, and the occurence of metabloic side effects induced by oncology treatments 5 years
Secondary All relevant statistical associations between new therapies to treat or prevent the metabolic side effects induced by oncology treatments, and overall survival 5 years
Secondary All relevant statistical associations between the pre therapeutic metabolic checkup and follow up for patients with cancer or history of cancer, and the occurence of metabolic toxicities of oncology treatments. 5 years
See also
  Status Clinical Trial Phase
Recruiting NCT05243446 - Cardiorenal Effecs of Losartan in Kidney Transplant Recipients
Completed NCT06089226 - Parameters Related to Physical Activity Level in SCI
Recruiting NCT04696081 - Atrial Fibrillation in Active Cancer Patients
Completed NCT05687097 - Untreated Sleep Apnea as an Aggravating Factor for Other Secondary Medical Conditions After Spinal Cord Injury
Completed NCT03274869 - Scrub Typhus Infection Induced Cardiovascular Disease
Completed NCT04025086 - Perioperative Goal Directed Therapy (PGDT) in Spinal Surgery in the Prone Position
Completed NCT03010969 - Perioperative Endothelial Dysfunction in Patients Undergoing Major Acute Abdominal Surgery
Completed NCT01413815 - Effect of the Amino Acid L-arginine on Perioperative Cardio-vascular Risk in Non-selected Patients N/A
Recruiting NCT05077748 - An 18-year Follow-up Study on OSA in a Population-based Cohort
Not yet recruiting NCT06279000 - Colchicine in Patients at Cardiac Risk Undergoing Major Non-Cardiac Surgery Phase 3
Enrolling by invitation NCT06360666 - Clinical Outcomes in Adult Patients Undergoing Laparoscopic Surgery Under Neuraxial Anesthesia
Recruiting NCT03977337 - Perioperative Pulmonary Monitoring in Major Emergency Surgery
Recruiting NCT05996965 - Evaluation of Clinical Utility of Non-invasive Hemodynamic Monitoring Device
Recruiting NCT05349955 - Effects and Safety of Diabetic GUideline Algorithm Implementation Performed by Primary Care Physicians in the Community N/A
Withdrawn NCT04435015 - The Utility of Camostat Mesylate in Patients With COVID-19 Associated Coagulopathy (CAC) and Cardiovascular Complications Phase 1/Phase 2
Active, not recruiting NCT05745090 - N-terminal Pro-B-type Natriuretic Peptide (NT-proBNP) in Type 2 Diabetes Mellitus
Terminated NCT03760159 - Minimally Invasive Detection of a Sleep Apnoea
Completed NCT04802122 - Induction of Anesthesia With Sevoflurane Preserving Spontaneous Breathing: Cardiorespiratory Effects. Phase 4
Not yet recruiting NCT06419270 - Cardiovascular, Renal, and Skeletal Complications in Patients With Post-Surgical Hypoparathyroidism
Recruiting NCT05895669 - Cardiovascular Outcomes in Orthotopic Liver Transplanted Patients (COLT Study)